These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10899516)

  • 41. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome.
    Homburg R; Levy T; Berkovitz D; Farchi J; Feldberg D; Ashkenazi J; Ben-Rafael Z
    Fertil Steril; 1993 Mar; 59(3):527-31. PubMed ID: 8458452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
    Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
    Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis.
    Agrawal R; Holmes J; Jacobs HS
    Fertil Steril; 2000 Feb; 73(2):338-43. PubMed ID: 10685540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age.
    Weghofer A; Margreiter M; Bassim S; Sevelda U; Beilhack E; Feichtinger W
    Fertil Steril; 2004 Apr; 81(4):1002-6. PubMed ID: 15066455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Increased incidence of ovarian hyperstimulation syndrome following combined GnRH agonist/hMG therapy].
    Lindner C; Braendle W; Köhler S; Bettendorf G
    Geburtshilfe Frauenheilkd; 1989 Apr; 49(4):337-44. PubMed ID: 2525500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
    Gizzo S; Andrisani A; Esposito F; Noventa M; Di Gangi S; Angioni S; Litta P; Gangemi M; Nardelli GB
    Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist.
    Williams SC; Gibbons WE; Muasher SJ; Oehninger S
    Fertil Steril; 2002 Nov; 78(5):1068-72. PubMed ID: 12413995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist for patients with repeated IVF failures and poor embryo quality.
    Orvieto R; Nahum R; Rabinson J; Gemer O; Anteby EY; Meltcer S
    Fertil Steril; 2009 Apr; 91(4 Suppl):1398-400. PubMed ID: 18675974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cessation of gonadotropin-releasing hormone analogue (GnRH-a) upon down-regulation versus conventional long GnRH-a protocol in poor responders undergoing in vitro fertilization.
    Dirnfeld M; Fruchter O; Yshai D; Lissak A; Ahdut A; Abramovici H
    Fertil Steril; 1999 Sep; 72(3):406-11. PubMed ID: 10519608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A multi-center, randomized controlled clinical trial of the application of a shortened protocol of long-acting Triptorelin down-regulated prior to IVF/ICSI among patients with endometriosis: A protocol.
    Kong H; Hu L; Nie L; Yu X; Dai W; Li J; Chen C; Bu Z; Shi H; Wu Q; Guan Y; Sun Y
    Reprod Health; 2018 Dec; 15(1):213. PubMed ID: 30572916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
    Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
    J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis.
    Xiao J; Chang S; Chen S
    Fertil Steril; 2013 Dec; 100(6):1594-601.e1-9. PubMed ID: 24055048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical pregnancy rates in an IVF program. Use of the flare-up protocol after failure with long regimens of GnRH-a.
    Karacan M; Erkan H; Karabulut O; Sarikamiş B; Camlibel T; Benhabib M
    J Reprod Med; 2001 May; 46(5):485-9. PubMed ID: 11396377
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial.
    Prapas Y; Petousis S; Dagklis T; Panagiotidis Y; Papatheodorou A; Assunta I; Prapas N
    Eur J Obstet Gynecol Reprod Biol; 2013 Jan; 166(1):43-6. PubMed ID: 23020996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
    Kedem A; Tsur A; Haas J; Yerushalmi GM; Hourvitz A; Machtinger R; Orvieto R
    Fertil Steril; 2014 Jun; 101(6):1624-8. PubMed ID: 24680364
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective randomized study of human menotropin versus a follicular and a luteal phase gonadotropin-releasing hormone analog-human menotropin stimulation protocols for in vitro fertilization.
    Maroulis GB; Emery M; Verkauf BS; Saphier A; Bernhisel M; Yeko TR
    Fertil Steril; 1991 Jun; 55(6):1157-64. PubMed ID: 1903732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What are the best predictors for successful GnRH antagonist protocol in in vitro fertilization (IVF) treatment?
    Samara N; Reis D; Danielli Miller N; Ghetler Y; Berkovitz A; Miller M; Gonen O; Shulman A; Wiser A
    Gynecol Endocrinol; 2015; 31(11):877-9. PubMed ID: 26416777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CA-125 concentrations in the serum and pregnancy outcome in IVF cycles.
    Brandenberger AW; Bersinger NA; Huber PR; Berger E; Glanzmann P; Birkhaeuser MH
    J Assist Reprod Genet; 1998 Jul; 15(6):390-4. PubMed ID: 9673885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study.
    Weigert M; Krischker U; Pöhl M; Poschalko G; Kindermann C; Feichtinger W
    Fertil Steril; 2002 Jul; 78(1):34-9. PubMed ID: 12095487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.